This article presents background information and highlights key findings from a managed care perspective related to enlarged prostate (EP) in Medicare-eligible patients. This article does not provide ...

Compared to placebo treatment, taking 5-alpha-reductase inhibitors (5-ARIs) can reduce a man's risk of being diagnosed with prostate cancer from around 5--9 percent to around 4-6 percent during up to ...

Please provide your email address to receive an email when new articles are posted on . A new clinical practice guideline issued jointly by the American Society of Clinical Oncology and the American ...

Prostate cancer remains a significant public health problem. The current approach with prostate-specific antigen (PSA)-based screening has questionable effects on prostate cancer–specific mortality ...

To earn CME related to this news article, click here. February 25, 2009 — A new joint guideline produced by the American Society of Clinical Oncology (ASCO) and the American Urological Association ...

: To evaluate the likelihood of alphaadrenergic antagonist (alpha-blocker) discontinuation in combination with dutasteride or finasteride among patients aged =65 years with enlarged prostate. Methods ...

Researchers conducted a retrospective matched cohort study to compare the risk of death among BPH patients treated with 5ARIs, as monotherapy or in combination with alpha-blockers, and those treated ...

Use of elevated baseline IL-8, CCL-2, and TNFα to predict for shorter overall survival (OS) in men with metastatic prostate cancer initiating androgen-deprivation therapy (ADT). Background: Active ...

The FDA has notified healthcare professionals that the Warnings and Precautions section of the labeling for the class of 5-alpha reductase inhibitors has been revised to include new safety information ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. While 5-alpha-reductase inhibitor use did not increase ...